NasdaqHealth CarePharmaceutical PreparationsSYDNEY NSW, Australia

Kazia Therapeutics Limited KZIA

Ask your AI

The newest share count in the company’s SEC filings is over 13 months oldCIK 1075880

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

10 added · 6 trimmed

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in Kazia Therapeutics Limited's latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No recent insider purchases or sales for this company.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

2.47M shares

31 funds report KZIA. Values checked against market prices.

Q3 2026. 10 new, 10 added to, 6 trimmed, 16 exited since Q2 2026.

Top 13F holders
#
1	Bleichroeder LP 13F ↗	490,410	$4.7M	+22.6%
2	Flputnam Investment Management Co 13F ↗	425,320	$4.1M	+2.5%
3	Stonepine Capital Management, LLC 13F ↗	377,429	$3.6M	+9.3%
4	Marshall Wace, LLP 13F ↗	357,505	$3.4M	+708.3%
5	UBS Group AG 13F ↗	170,613	$1.6M	+110.4%
6	Ensign Peak Advisors, Inc 13F ↗	92,589	$888.4K	-16.4%
7	BNP Paribas Financial Markets 13F ↗	84,852	$814.2K	+182.0%
8	Barclays plc 13F ↗	60,999	$585.3K	+7.0%
9	Westside Investment Management, Inc. 13F ↗	56,835	$545.3K	+19.4%
10	Kalehua Capital Management LLC 13F ↗	56,013	$537.4K	New

Download CSV Every fund that holds KZIA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Kazia Therapeutics Limited and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Kazia Therapeutics Limited and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2025	10	—	144,017	$902.9K
Q3 2025	11	+1	158,075	$1.1M
Q4 2025	22	+11	2.48M	$17.1M
Q1 2026	23	+1	1.75M	$13.0M
Q2 2026	36	+13	3.64M	$50.7M
Q3 2026	31	-5	2.47M	$23.7M

Each point is a quarter-end, from Q2 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (48669G303). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes11 in 12 mo 8-K eventsNone in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials0 active IPO history6 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: KAZIA THERAPEUTICS LTD
Address: THREE INTERNATIONAL TOWERS LEVEL 24,, 300 BARANGAROO AVENUE, SYDNEY NSW, Australia 2000
Phone: 01161298780088
Fiscal year ends: Jun 30
Filer category: Non-accelerated filer
Incorporated in: Australia
Listed as: KZIA (Nasdaq)
Former names: NOVOGEN LTD (until 2017)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$6.62−$0.33 (−4.75%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $6.62 · High $8.72Nov 13, 2026

Aug 13, 2026Low $6.62 · High $16.90Nov 13, 2026

Nov 13, 2025Low $5.00 · High $16.90Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.